Opinion

Video

Introduction and Current Landscape of HER2 in NSCLC

Key Takeaways

  • HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies.
  • Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine are key HER2-directed therapies recommended by NCCN guidelines for HER2-positive NSCLC.
SHOW MORE

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.

Video content above is prompted by the following:

  • Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms.
  • (Bazhenova) Describe the difference between HER2 mutation and HER2 expression.
  • (Kim) Provide an overview of the current HER2-directed therapies (fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine) available and how they’re recommended in the NCCN guidelines.
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo